Gower Bob G reported conversion involving 254,307 derivative units of Ensysce Biosciences, Inc. on Apr 23, 2026

Conversion
Form 4 code C. Conversion of a derivative security.
Director
DIR
Filed Aug 18, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
254,307Warrant
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
289,836Direct
Trade date
Apr 23, 2026Conversion
Filed
Aug 18, 2026, 6:06 AM ET117-day reporting delay
Accession
0001493152-26-038866Code C · Transaction 1532
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Apr 23, 2026Buy508,614$0.48$246,169.18Trade 1530
Aug 7, 2026Buy400,000$0.50$198,000Trade 1531
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
2 warnings
delayed filingThe filing was reported 117 calendar days after the transaction date.
missing priceThe filing did not provide a usable price per share.

ENSC price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ENSC · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +58%1w ago +42%1d ago +42%
Returns since7d −2.6%30d +16%90d180d1y

Footnotes in full

F1: The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person. F2: Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.